Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from TrivarX Limited ( (AU:TRI) ) is now available.
TrivarX Limited reported positive results from a clinical trial evaluating its single-lead ECG algorithm designed to detect major depressive episodes (cMDE) in U.S. veterans. The trial, conducted in collaboration with the Greater Los Angeles Research and Education Foundation and the VA Greater Los Angeles Healthcare System, showcased the algorithm’s impressive sensitivity of 97%, underlining its potential to improve early detection of mental health conditions in veterans. The technology’s ability to integrate into existing clinical workflows supports efficient adoption and aligns with the VA’s priorities, strengthening TrivarX’s market position and paving the way for broader clinical and commercial opportunities.
More about TrivarX Limited
TrivarX Limited operates in the healthcare technology industry. The company focuses on developing advanced diagnostic tools, including ECG-based algorithms, to address mental health conditions such as depression and PTSD, particularly in complex patient populations like veterans.
YTD Price Performance: 6.25%
Average Trading Volume: 3,155,901
Technical Sentiment Signal: Sell
Current Market Cap: A$12.17M
Learn more about TRI stock on TipRanks’ Stock Analysis page.